{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-028506","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.939643+00:00","generated_at":"2026-06-11T11:45:08.354417+00:00","sec_items":["2.02","9.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"AgeX CEO steps down; cash only $0.3M, substantial doubt about going concern","bullets":["Net loss $2.7M Q2 2023 ($0.07/sh), consistent YoY; cash $0.3M.","Juvenescence exchanged $36M debt for preferred shares in July 2023; remaining debt $1.2M.","CEO Michael West stepped down; Joanne Hackett appointed Interim CEO.","Jean-Christophe Renondin appointed to Board; possible merger with Serina mentioned.","Company expresses substantial doubt about ability to continue as going concern."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-028506","json":"https://secwatch.observer/filing/0001493152-23-028506.json","markdown":"https://secwatch.observer/filing/0001493152-23-028506.md","text":"https://secwatch.observer/filing/0001493152-23-028506.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223028506/0001493152-23-028506-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223028506/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T11:45:08.354417+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7982d0956fa456069071f8333b8cf59f9553ea23","claim":"Serina Therapeutics, Inc. reported second quarter 2023 ended June 30, 2023 results: net income $2.7 million net loss attributable to AgeX for the three months ended June 30, 2023, EPS ($0.07) per share (basic and diluted).","evidence_excerpt":"the net loss attributable to AgeX for the three months ended June 30, 2023 was $2.7 million, or ($0.07) per share (basic and diluted) compared to $2.6 million, or ($0.07) per share (basic and diluted), for 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223028506/0001493152-23-028506-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter 2023 ended June 30, 2023"},{"label":"Net income","value":"$2.7 million net loss attributable to AgeX for the three months ended June 30, 2023"},{"label":"EPS","value":"($0.07) per share (basic and diluted)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}